S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:BPTS

Biophytis (BPTS) Stock Price, News & Analysis

$0.35
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$0.35
$0.39
50-Day Range
$0.36
$0.60
52-Week Range
$0.33
$5.19
Volume
48,532 shs
Average Volume
67,684 shs
Market Capitalization
$3.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Biophytis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
4,185.7% Upside
$15.00 Price Target
Short Interest
Healthy
0.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of Biophytis in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.06) to ($0.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.52 out of 5 stars

BPTS stock logo

About Biophytis Stock (NASDAQ:BPTS)

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

BPTS Stock Price History

BPTS Stock News Headlines

Biophytis (NASDAQ:BPTS) Stock Price Down 1.6%
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Biophytis (BPTS) Soars 73% on Partnership With Skyepharma
Why Biophytis (BPTS) Shares Are Sky-Rocketing
Biophytis Shares Surge 79% Following Covid-19 Partnership With Skyepharma
Why Is Biophytis (BPTS) Stock Up 49% Today?
See More Headlines
Receive BPTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
4/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BPTS
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+4,064.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.84) per share

Miscellaneous

Free Float
9,375,000
Market Cap
$3.51 million
Optionable
Not Optionable
Beta
1.09
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Stanislas Veillet Ph.D. (Age 59)
    Chairman of the Board & CEO
    Comp: $468.64k
  • Mr. Nicolas Fellmann (Age 56)
    Chief Financial Officer
  • Mr. Waly Dioh Ph.D. (Age 55)
    Chief Clinical Operating Officer
  • Dr. Pierre J. Dilda (Age 54)
    Chief Scientific Officer
  • Dr. Rene Lafont (Age 78)
    Scientific Advisor & Member of Scientific Advisory Board
  • Dr. Rob van Maanen FFPM (Age 54)
    M.B.A., M.D., Chief Medical Officer
  • Mr. Edouard Bieth
    Chief Business Officer
  • Ms. _ Teylan
    Financial Controller

BPTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Biophytis stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biophytis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPTS shares.
View BPTS analyst ratings
or view top-rated stocks.

What is Biophytis' stock price target for 2024?

1 brokers have issued twelve-month price targets for Biophytis' shares. Their BPTS share price targets range from $15.00 to $15.00. On average, they expect the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 4,185.7% from the stock's current price.
View analysts price targets for BPTS
or view top-rated stocks among Wall Street analysts.

How have BPTS shares performed in 2024?

Biophytis' stock was trading at $0.6707 at the beginning of the year. Since then, BPTS shares have decreased by 47.8% and is now trading at $0.35.
View the best growth stocks for 2024 here
.

Are investors shorting Biophytis?

Biophytis saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 42,900 shares, an increase of 44.4% from the February 29th total of 29,700 shares. Based on an average trading volume of 66,100 shares, the short-interest ratio is currently 0.6 days.
View Biophytis' Short Interest
.

When is Biophytis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 16th 2024.
View our BPTS earnings forecast
.

When did Biophytis' stock split?

Shares of Biophytis reverse split before market open on Thursday, March 30th 2023. The 1-10 reverse split was announced on Thursday, March 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Biophytis IPO?

Biophytis (BPTS) raised $20 million in an initial public offering on Wednesday, February 10th 2021. The company issued 1,200,000 shares at $15.00-$18.00 per share. H.C. Wainwright served as the underwriter for the IPO.

How do I buy shares of Biophytis?

Shares of BPTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BPTS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners